FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360754741> ?p ?o ?g. }

• W4360754741 abstract "Background In nephrotic syndrome protein leaks from the blood to the urine through the glomeruli resulting in hypoproteinaemia and generalised oedema. While most children with nephrotic syndrome respond to corticosteroids, 80% experience a relapsing course. Corticosteroids have reduced the mortality rate to around 3%. However corticosteroids have well recognised potentially serious adverse effects such as obesity, poor growth, hypertension, diabetes mellitus, osteoporosis and behavioural disturbances. This is an update of a review first published in 2000 and updated in 2003, 2005 and 2007. Objectives The aim of this review was to assess the benefits and harms of different corticosteroid regimens in children with steroid‐sensitive nephrotic syndrome (SSNS). The benefits and harms of therapy were studied in two groups of children 1) children in their initial episode of SSNS, and 2) children who experience a relapsing course of SSNS. Search methods We searched the Cochrane Renal Group's Specialised Register to 26 February 2015 through contact with the Trials Search Co‐ordinator using search terms relevant to this review. Selection criteria Randomised controlled trials (RCTs) performed in children (three months to 18 years) in their initial or subsequent episode of SSNS, comparing different durations, total doses or other dose strategies using any corticosteroid agent. Data collection and analysis Two authors independently assessed risk of bias and extracted data. Results were expressed as risk ratio (RR) or mean difference (MD) with 95% confidence intervals (CI). Main results Ten new studies were identified so a total of 34 studies (3033 total participants) were included in the 2015 review update. The risk of bias attributes were frequently poorly performed. Low risk of bias was reported in 18 studies for sequence generation, 16 studies for allocation concealment, seven for performance and detection bias, 15 for incomplete reporting and 16 for selective reporting. Three months or more of prednisone significantly reduced the risk of frequently relapsing nephrotic syndrome (FRNS) (6 studies, 582 children: RR 0.68, 95% CI 0.47 to 1.00) and of relapse by 12 to 24 months (8 studies, 741 children: RR 0.80, 95% CI 0.64 to 1.00) compared with two months. Five or six months of prednisone significantly reduced the risk of relapse (7 studies, 763 children: RR 0.62, 95% CI 0.45 to 0.85) but not FRNS (5 studies, 591 children: RR 0.78, 95% CI 0.50 to 1.22) compared with three months. However there was significant heterogeneity in the analyses. Subgroup analysis stratified by risk of bias for allocation concealment showed that the risk for FRNS did not differ significantly between two or three months of prednisone and three to six months among studies at low risk of bias but was significantly reduced in extended duration studies compared with two or three months in studies at high risk or unclear risk of bias. There were no significant differences in the risk of adverse effects between extended duration and two or three months of prednisone. Four studies found that in children with FRNS, daily prednisone during viral infections compared with alternate‐day prednisone or no treatment significantly reduced the rate of relapse. Authors' conclusions In this 2015 update the addition of three well‐designed studies has changed the conclusion of this review. Studies of long versus shorter duration of corticosteroids have heterogeneous treatment effects, with the older high risk of bias studies tending to over‐estimate the effect of longer course therapy, compared with more recently published low risk of bias studies. Among studies at low risk of bias, there was no significant difference in the risk for FRNS between prednisone given for two or three months and longer durations or total dose of therapy indicating that there is no benefit of increasing the duration of prednisone beyond two or three months in the initial episode of SSNS. The risk of relapse in children with FRNS is reduced by the administration of daily prednisone at onset of an upper respiratory tract or viral infection. Three additional studies have increased the evidence supporting this conclusion. This management strategy may be considered for children with FRNS. A paucity of data on prednisone use in relapsing nephrotic syndrome remains. In particular there are no data from RCTs evaluating the efficacy and safety of prolonged courses of low dose alternate‐day prednisone although this management strategy is recommended in current guidelines." @default.
• W4360754741 created "2023-03-25" @default.
• W4360754741 creator A5015680276 @default.
• W4360754741 creator A5030548857 @default.
• W4360754741 creator A5051609819 @default.
• W4360754741 creator A5056074771 @default.
• W4360754741 date "2015-03-18" @default.
• W4360754741 modified "2023-10-17" @default.
• W4360754741 title "Corticosteroid therapy for nephrotic syndrome in children" @default.
• W4360754741 cites W123835664 @default.
• W4360754741 cites W1491720051 @default.
• W4360754741 cites W1568115331 @default.
• W4360754741 cites W1898915641 @default.
• W4360754741 cites W1965888315 @default.
• W4360754741 cites W1967091682 @default.
• W4360754741 cites W1967181593 @default.
• W4360754741 cites W1968348071 @default.
• W4360754741 cites W1969400644 @default.
• W4360754741 cites W1969653216 @default.
• W4360754741 cites W1972855150 @default.
• W4360754741 cites W1973431144 @default.
• W4360754741 cites W1975979343 @default.
• W4360754741 cites W1976715450 @default.
• W4360754741 cites W1984157532 @default.
• W4360754741 cites W1988542691 @default.
• W4360754741 cites W1994069320 @default.
• W4360754741 cites W1996339513 @default.
• W4360754741 cites W1998220895 @default.
• W4360754741 cites W1998442004 @default.
• W4360754741 cites W2005554822 @default.
• W4360754741 cites W2006204620 @default.
• W4360754741 cites W2006815696 @default.
• W4360754741 cites W2008965640 @default.
• W4360754741 cites W2016524458 @default.
• W4360754741 cites W2017206130 @default.
• W4360754741 cites W2021397728 @default.
• W4360754741 cites W2023127090 @default.
• W4360754741 cites W2026433234 @default.
• W4360754741 cites W2029689046 @default.
• W4360754741 cites W2034812514 @default.
• W4360754741 cites W2035851258 @default.
• W4360754741 cites W2038372397 @default.
• W4360754741 cites W2040766157 @default.
• W4360754741 cites W2043195418 @default.
• W4360754741 cites W2044626711 @default.
• W4360754741 cites W2047135575 @default.
• W4360754741 cites W2047716331 @default.
• W4360754741 cites W2049321668 @default.
• W4360754741 cites W2051483026 @default.
• W4360754741 cites W2053037831 @default.
• W4360754741 cites W2060618888 @default.
• W4360754741 cites W2074546250 @default.
• W4360754741 cites W2077144308 @default.
• W4360754741 cites W2084620309 @default.
• W4360754741 cites W2087434766 @default.
• W4360754741 cites W2088616569 @default.
• W4360754741 cites W2089913116 @default.
• W4360754741 cites W2090481397 @default.
• W4360754741 cites W2090656123 @default.
• W4360754741 cites W2090897475 @default.
• W4360754741 cites W2091427149 @default.
• W4360754741 cites W2092953388 @default.
• W4360754741 cites W2094025446 @default.
• W4360754741 cites W2099611336 @default.
• W4360754741 cites W2101944817 @default.
• W4360754741 cites W2103254544 @default.
• W4360754741 cites W2115161561 @default.
• W4360754741 cites W2122941588 @default.
• W4360754741 cites W2125435699 @default.
• W4360754741 cites W2127974114 @default.
• W4360754741 cites W2134338262 @default.
• W4360754741 cites W2134425923 @default.
• W4360754741 cites W2134772591 @default.
• W4360754741 cites W2135333084 @default.
• W4360754741 cites W2135914496 @default.
• W4360754741 cites W2139101671 @default.
• W4360754741 cites W2144487897 @default.
• W4360754741 cites W2145601642 @default.
• W4360754741 cites W2145810533 @default.
• W4360754741 cites W2160430974 @default.
• W4360754741 cites W2168584903 @default.
• W4360754741 cites W2169596284 @default.
• W4360754741 cites W2169959239 @default.
• W4360754741 cites W2301544544 @default.
• W4360754741 cites W2313982312 @default.
• W4360754741 cites W2336670394 @default.
• W4360754741 cites W2337791726 @default.
• W4360754741 cites W2416515146 @default.
• W4360754741 cites W4205615509 @default.
• W4360754741 cites W4211122467 @default.
• W4360754741 cites W4214559180 @default.
• W4360754741 cites W4235236328 @default.
• W4360754741 cites W4238506241 @default.
• W4360754741 cites W4240138201 @default.
• W4360754741 cites W4251694231 @default.
• W4360754741 cites W4254273269 @default.
• W4360754741 cites W4360754741 @default.
• W4360754741 doi "https://doi.org/10.1002/14651858.cd001533.pub5" @default.
• W4360754741 hasPublicationYear "2015" @default.
• W4360754741 type Work @default.

• next